tudy on Biomarkers Using Circulating Tumor Cells When Administering Osimertinib in Patients with EGFR Mutation-positive Lung Cancer
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000032055
- Lead Sponsor
- Toho University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with complications or a history of serious lung disorder 2) Patients with intermediate or serious liver disorder 3) Patients with complications or a history of serious QT prolongation (QTc value longer than 500msec, symptom of serious arrhythmia) 4) Pregnant women, women who may possibly be pregnant, women who hope to be pregnant, lactating women and men who declined contraception 5) Patients positive for human immunodeficiency virus (HIV) 6) Patients positive for HBs antigen or hepatitis C virus (HCV RNA) 7) Other patients considered as
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method